PDF
Recommendation on the Use of Live Attenuated Influenza Vaccine (LAIV) in HIV-Infected Individuals
Organization: Public Health Agency of Canada (PHAC)Published: 2020
"The objective of this advisory committee statement is to review the efficacy and effectiveness, immunogenicity, and safety evidence on LAIV use in HIV-infected individuals and to provide updated guidance on the use of LAIV in this population." - Recommendation on the Use of Live Attenuated Influenza Vaccine (LAIV) in HIV-Infected Individuals
Resource Group:
Implementation Tool
Product Type: Guide
Program Delivery and Evaluation
Clinics
Vaccine Preventable Diseases
Communicable Diseases
Influenza
Specific Populations
Children
High Risk Children
Product Type: Guide
Category:
Program Planning and Delivery,Program Delivery and Evaluation,Clinics,Vaccine Preventable Diseases,Communicable Diseases,Influenza,Specific Populations,Children,High Risk Children Program Planning and DeliveryProgram Delivery and Evaluation
Clinics
Vaccine Preventable Diseases
Communicable Diseases
Influenza
Specific Populations
Children
High Risk Children
Language:
English
LinkResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.